PMID- 17608923
OWN - NLM
STAT- MEDLINE
DCOM- 20070823
LR  - 20181113
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 7
DP  - 2007 Jul 3
TI  - A full scale comparative study of methods for generation of functional Dendritic 
      cells for use as cancer vaccines.
PG  - 119
AB  - BACKGROUND: Dendritic cells (DCs) are professional antigen-presenting cells with 
      the ability to induce primary T-cell responses and are commonly produced by 
      culturing monocytes in the presence of IL-4 and GM-CSF for 5-7 days (Standard 
      DC). Recently, Dauer and co-workers presented a modified protocol for 
      differentiation of human monocytes into mature DCs within 48 hours (Fast DC). 
      Here we report a functional comparison of the two strategies for generation of 
      DCs from human monocytes with adaptions for large-scale clinical use. METHODS: 
      The Elutra Cell Selection System was used to isolate monocytes after collection 
      of leukapheresis product. The enriched monocytes were cultured in gas permeable 
      Teflon bags with IL-4 and GM-CSF for 24 hours (Fast DC) or 5 days (Standard DC) 
      to obtain immature DCs. The cells were then transfected with mRNA from the 
      leukemia cell line Jurkat E6 by electroporation and incubated for additional 24 h 
      or 2 days in the presence of pro-inflammatory cytokines (TNFalpha, IL-1beta, IL-6 
      and PGE2) to obtain mature DCs. RESULTS: Mature Fast DC and Standard DC displayed 
      comparable levels of many markers expressed on DC, including HLA-DR, CD83, CD86, 
      CD208 and CCR7. However, compared to Standard DC, mature Fast DC was CD14high 
      CD209low. Fast DC and Standard DC transfected with Jurkat E6-cell mRNA were 
      equally able to elicit T cell specifically recognizing transfected DCs in vitro. 
      IFNgamma-secreting T cells were observed in both the CD4+ and CD8+ subsets. 
      CONCLUSION: Our results indicate that mature Fast DC are functional antigen 
      presenting cells (APCs) capable of inducing primary T-cell responses, and suggest 
      that these cells may be valuable for generation of anti-tumor vaccines.
FAU - Jarnjak-Jankovic, Silvija
AU  - Jarnjak-Jankovic S
AD  - Department of Pediatric Research, The National Hospital, Oslo, Norway. 
      silvija.jankovic@rr-research.no
FAU - Hammerstad, Hege
AU  - Hammerstad H
FAU - Saeboe-Larssen, Stein
AU  - Saeboe-Larssen S
FAU - Kvalheim, Gunnar
AU  - Kvalheim G
FAU - Gaudernack, Gustav
AU  - Gaudernack G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20070703
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Cancer Vaccines)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Antigen-Presenting Cells/immunology
MH  - Blood Component Removal
MH  - Cancer Vaccines/immunology/*pharmacology
MH  - Cell Culture Techniques/methods
MH  - Cell Line, Tumor
MH  - Dendritic Cells/cytology/*immunology
MH  - Humans
MH  - Immunomagnetic Separation
MH  - Immunophenotyping
MH  - Male
MH  - Monocytes/*cytology
MH  - Neoplasms/*prevention & control
MH  - RNA, Messenger
MH  - Sensitivity and Specificity
MH  - T-Lymphocytes/immunology
MH  - Transfection
PMC - PMC1931601
EDAT- 2007/07/05 09:00
MHDA- 2007/08/24 09:00
PMCR- 2007/07/03
CRDT- 2007/07/05 09:00
PHST- 2007/02/27 00:00 [received]
PHST- 2007/07/03 00:00 [accepted]
PHST- 2007/07/05 09:00 [pubmed]
PHST- 2007/08/24 09:00 [medline]
PHST- 2007/07/05 09:00 [entrez]
PHST- 2007/07/03 00:00 [pmc-release]
AID - 1471-2407-7-119 [pii]
AID - 10.1186/1471-2407-7-119 [doi]
PST - epublish
SO  - BMC Cancer. 2007 Jul 3;7:119. doi: 10.1186/1471-2407-7-119.